Medically reviewed on September 10, 2018
(poe DOF il oks)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Condylox: 0.5% (3.5 g)
Condylox: 0.5% (3.5 mL [DSC]) [contains alcohol, usp]
Generic: 0.5% (3.5 mL)
Brand Names: U.S.
- Keratolytic Agent
- Topical Skin Product
Exact mechanism of action is unknown; causes necrosis of visible wart tissue
No detectable serum levels
Use: Labeled Indications
Genital warts: Treatment of external genital warts
Perianal warts: Treatment of perianal warts (gel only)
Off Label Uses
Data from a randomized, multicenter, double-blind, placebo-controlled study support the use of podofilox in the treatment of molluscum contagiosum [Syed 1994].
Hypersensitivity or intolerance to any component of the formulation
Genital warts: Topical: Solution: Apply twice daily (morning and evening) for 3 consecutive days, then withhold use for 4 consecutive days; this cycle may be repeated up to 4 times until there is no visible wart tissue; maximum dose: 0.5 mL daily (or ≤10 cm2 of wart tissue). Note: Discontinue after 4 treatment cycles if incomplete response and consider alternative treatment; do not repeat use.
Genital and perianal warts: Topical: Gel: Apply twice daily (morning and evening) for 3 consecutive days, then withhold use for 4 consecutive days; this cycle may be repeated up to 4 times until there is no visible wart tissue; maximum dose: 0.5 g daily (or ≤10 cm2 of wart tissue). Note: Discontinue after 4 treatment cycles if incomplete response and consider alternative treatment; do not repeat use.
Molluscum contagiosum (off-label use): Topical: Gel or solution: Apply twice daily (morning and evening) for 3 consecutive days, then withhold use for 4 consecutive days; this cycle may be repeated up to 4 times until there is no visible wart tissue (Syed 1994)
Refer to adult dosing.
For external use only. Do not apply to mucous membrane warts. Wash hands before and after application. Apply to warts using either the applicator supplied with the drug (gel, solution) or with finger (gel only) while minimizing exposure to surrounding normal tissue. Dispose applicator tip carefully after use. Allow the gel or solution to dry before allowing return of opposing skin surfaces to their normal positions; wash hands after application.
Store at 20°C to 25°C (68°F to 77°F); do not freeze. Flammable; avoid excessive heat and flame.
There are no known significant interactions.
Central nervous system: Localized burning (12% to 37%), local pain (12% to 24%)
Dermatologic: Skin erosion (9% to 27%)
Hematologic & oncologic: Local hemorrhage (<1% to 19%)
Local: Local inflammation (9% to 32%), local pruritus (8% to 32%)
1% to 10%:
Central nervous system: Headache (7%)
Dermatologic: Stinging of the skin (7%), erythema (5%)
<1%, postmarketing, and/or case reports: Crusted skin, dermal ulcer, desquamation, edema, skin blister, skin discoloration, skin fissure, skin rash, skin tenderness, tingling of skin, xeroderma
Central nervous system: Localized burning (female 78%; male 64%), local pain (female 72%; male 50%)
Dermatologic: Skin erosion (67%)
Local: Local inflammation (male 71%; female 63%), local pruritus (female 65%; male 50%)
<1%, postmarketing, and/or case reports: Body odor, dermal ulcer, dizziness, hematuria, insomnia, local hemorrhage, localized edema, localized vesiculation, pain, skin tenderness, tingling of skin, vomiting, xeroderma
Concerns related to adverse effects:
• Skin reactions: Most skin reactions are mild to moderate and did not increase during the treatment period, however severe skin reactions can occur. Severe reactions are most frequent within the first two weeks of treatment.
Dosage form specific issues:
• Topical gel and solution: Flammable; keep away from fire or flame.
• Appropriate use: For cutaneous use only; avoid contact with eyes. If product comes in contact with the eyes, flush with water and seek medical attention. Not intended for treatment of mucous membrane warts.
Treated areas for adequate healing; tolerability of treatment
Teratogenic events have not been observed in animal reproduction studies with topical administration. Podofilox should not be used during pregnancy (CDC [Workowski 2015])
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience burning, itching, or short-term pain. Have patient report immediately to prescriber severe skin irritation, severe pain, edema, or bleeding (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about podofilox topical
- Podofilox topical Side Effects
- During Pregnancy
- Dosage Information
- Support Group
- Pricing & Coupons
- En Español
- 28 Reviews
- Drug class: topical keratolytics
Other brands: Condylox